UNSPSC 51161704: Colfosceril

This classification denotes an agent affecting respiratory system with the molecular formula C40H80NO8P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 319X2NFW0A, chemically known as 3,5,9-trioxa-4-phosphapentacosan-1-aminium, 4-hydroxy-n,n,n-trimethyl-10-oxo-7-((1-oxohexadecyl)oxy)-, inner salt, 4-oxide but generally known as colfosceril palmitate, which bears US NIH Compound Identifier 6138.

UNSPSC 51161704 Colfosceril, a Commodity code, does not align with the state and local procurement activity currently tagged to it. The code nominally describes colfosceril, a synthetic lung surfactant used in neonatal respiratory therapy, but the recent opportunities posted under this code track instead to pharmacy services, naloxone procurement, generic pharmaceutical supply, and direct-to-manufacturer prescription programs — none of which involve colfosceril as a product or service input. The mismatch suggests either a tagging error in the source data or that this code is not actively used for state and local purchasing in the current procurement cycle.

The recent opportunities do, however, reveal active state and local demand for pharmaceutical supply and pharmacy services across multiple jurisdictions and issuing-body types. Hall County, Georgia issued an RFQ/P for on-site pharmacy services at a family health center clinic serving approximately 3,005 covered individuals, with responses due June 4, 2026. Seminole County, Florida posted an IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually through July 26, 2023 (note: this date is inconsistent with the June 30, 2026 posting date and likely reflects a data-entry error in the source). The Texas Health and Human Services Commission issued an RFI on direct-to-manufacturer prescription programs as a market-intelligence precursor to formal procurement. The Minnesota Department of Administration's Office of State Procurement, administering the MMCAP cooperative purchasing program, issued an RFP for generic multi-source pharmaceuticals and OTC products to supply state and local government facilities across multiple states, with proposals due March 26, 2026. The geographic spread spans Florida, Georgia, Texas, and Minnesota, with cooperative purchasing vehicles expanding access regionally. Given the code-to-opportunity mismatch, prospective vendors should verify the correct UNSPSC categorization before pursuing work in pharmaceutical supply or pharmacy services — these opportunities do not appear to be systematically tagged to colfosceril procurement.